Deadline: 8-Mar-22
The French National Research Agency, in partnership with seventeen countries (Belgium, Canada, Czech Republic, Denmark, Estonia, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Moldova, Poland, Spain, Sweden, Switzerland, United Kingdom) is launching the fourteenth call for proposals under the umbrella of the JPIAMR.
This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents. Proposals should focus on licenced antimicrobials agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should focus on one or more of the One Health settings (humans, animals, plants).
Topics
- Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
- Drug/plant protection agent repurposing;
- Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
- Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
- Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.
- The following sub-topics are out of scope of the call:
- Antiviral and antiparasitic agents
- Discovery and/or screening of new compounds, new vaccines and/or new targets
- Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)
Funding Information
The initiative aims to promote international research on antimicrobial resistance. The total budget for this action is 18.9 million euros.
Eligibility Criteria
- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries2 ).
- The consortium can include a maximum of six (6) project partners (including non-funded partners, Figure 1). The maximum number of partners can be increased to seven (7) if at least a partner from an under-represented country 3 (including LMICs 4 ) or a company is included in the consortium.
- Additional National Rules and Regulations (Annex B) of funders also apply and must be respected.
- Project partners not eligible for funding (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisations) may be involved in projectsif they bring their own funding. The budget of non-funded partners shall not exceed 30% of the requested total transnational project budget.
- A Project partner not eligible to be funded cannot be the coordinator of a proposal and, like funded members, must accept all JPIAMR rules and guidelines.
- At both the pre- and full proposal stage, all partners, including non-funded partners, must submit a signed letter of intent along with their pre-/full proposal. In the absence of these letters, the proposal will be declared ineligible.
For more information, visit French National Research Agency.
For more information, visit https://anr.fr/en/call-for-proposals-details/call/disrupting-drug-resistance-using-innovative-design-jpiamr-druid/
